Correlates of Osteoprotegerin and Association with Aortic Pulse Wave Velocity in Patients with Chronic Kidney Disease
- 1 November 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 6 (11), 2612-2619
- https://doi.org/10.2215/cjn.03910411
Abstract
Background and objectives Osteoprotegerin (OPG), a cytokine that regulates bone resorption, has been implicated in the process of vascular calcification and stiffness. Design, setting, participants, & measurements Serum OPG was measured in 351 participants with chronic kidney disease (CKD) from one site of the Chronic Renal Insufficiency Cohort Study. Cortical bone mineral content (BMC) was measured by quantitative computed tomography in the tibia. Multivariable linear regression was used to test the association between serum OPG and traditional cardiovascular risk factors, measures of abnormal bone and mineral metabolism, and pulse wave velocity. Results Higher serum OPG levels were associated with older age, female gender, greater systolic BP, lower estimated GFR, and lower serum albumin. OPG was not associated with measures of abnormal bone or mineral metabolism including serum phosphorus, albumin-corrected serum calcium, intact parathyroid hormone, bone-specific alkaline phosphatase, or cortical BMC. Among 226 participants with concurrent aortic pulse wave velocity measurements, increasing tertiles of serum OPG were associated with higher aortic pulse wave velocity after adjustment for demographics, traditional vascular risk factors, and nontraditional risk factors such as estimated GFR, albuminuria, serum phosphate, corrected serum calcium, presence of secondary hyperparathyroidism, serum albumin, and C-reactive protein or after additional adjustment for cortical BMC in a subset (n = 161). Conclusions These data support a strong relationship between serum OPG and arterial stiffness independent of many potential confounders including traditional cardiovascular risk factors, abnormal bone and mineral metabolism, and inflammation.Keywords
This publication has 43 references indexed in Scilit:
- Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patientsOsteoporosis International, 2010
- Biomarkers of the Osteoprotegerin PathwayArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- Aortic PWV in Chronic Kidney Disease: A CRIC Ancillary StudyAmerican Journal of Hypertension, 2010
- Inhibition of Receptor Activator of NF-κB Ligand by Denosumab Attenuates Vascular Calcium Deposition in MiceThe American Journal of Pathology, 2009
- Improving Global Outcomes in Mineral and Bone DisordersClinical Journal of the American Society of Nephrology, 2008
- Relationship of Calcification of Atherosclerotic Plaque and Arterial Stiffness to Bone Mineral Density and Osteoprotegerin in Postmenopausal Women Referred for Osteoporosis ScreeningCalcified Tissue International, 2008
- Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patientsNephrology Dialysis Transplantation, 2008
- The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysisNephrology Dialysis Transplantation, 2008
- Relations of Inflammatory Biomarkers and Common Genetic Variants With Arterial Stiffness and Wave ReflectionHypertension, 2008
- Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in
ldlr
(−/−)
MiceCirculation, 2008